Ads
related to: multiple myeloma- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Contact a Representative
Search results
AbbVie makes oncology progress with two drug trials
Crain s Chicago Business· 1 day agoMultiple myeloma, the second-most common blood cancer, is characterized by abnormal proliferation of plasma cells, which can cause end-organ damage, AbbVie ...
GSK blood cancer drug nearly halves risk of death in late-stage trial
Reuters via AOL· 6 days agoGSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared...
AbbVie treats first subject in Phase III multiple myeloma drug trial
Clinical Trials Arena via Yahoo Finance· 2 days agoAbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational...
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
Zacks via Yahoo Finance· 1 day agoThe late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with...
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 4 days agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
Become part of a movement to accelerate a cure for multiple myeloma!
Digital Journal· 3 days agoPRESS RELEASE Published June 5, 2024 24-7 Press Release Multiple Myeloma Research Foundation® Walk/Run DETROIT, MI, June 05, 2024 /24-7PressRelease/ -- ...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both...
Valley City Times Record· 4 days agoThe rates of deep and sustained MRD negativity were associated with improved progression-free...
Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myeloma
MedPage Today· 4 days agoTwo trials show positive outcomes
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated ...
Benzinga via AOL· 4 days agoThe data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On...
TECVAYLI® (teclistamab-cqyv) shows sustained deep and durable responses in patients with relapsed or...
Forrest City Times-Herald· 5 days ago"With the longest follow-up of any bispecific antibody, teclistamab demonstrates continued deep and durable responses observed in patients with relapsed or refractory multiple
Ad
related to: multiple myeloma